Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Highlights from IMW 2019 Part I

Francesca Gay and Katja Weisel • 25 Sep 2019
IMW 2019
Multiple Myeloma Antibodies Carfilzomib Daratumumab Dexamethasone Isatuximab Rituximab Thalidomide
CASSIOPEIA

Katja Weisel, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, and Francesca Gay, MD, University of Turin, Turin, Italy, discuss highlights from the International Myeloma Workshop (IMW) 2019, held in Boston, MA, with particular focus on the CASSIOPEIA trial (NCT02541383) and the future of measurable residual disease (MRD) in myeloma treatment.

More from Francesca Gay

An insight into designing randomized studies in high-risk myeloma
Binod Dhakal et al. • 4 Nov 2024
FORTE: MRD by MFC or NGS in myeloma 1:46
FORTE: MRD by MFC or NGS in myeloma
Francesca Gay • 14 Dec 2020
MRD: Paving the way for future clinical trials in myeloma 1:30
MRD: Paving the way for future clinical trials in myeloma
Francesca Gay • 14 Dec 2020
FORTE: KRd versus KCd treatment for myeloma 0:45
FORTE: KRd versus KCd treatment for myeloma
Francesca Gay • 14 Dec 2020

More from Katja Weisel

DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myeloma 1:02
DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myeloma
Katja Weisel • 3 Jun 2023
Ocular adverse events with ADCs 1:28
Ocular adverse events with ADCs
Katja Weisel • 10 Sep 2021
ADCs for the treatment of myeloma 3:02
ADCs for the treatment of myeloma
Katja Weisel • 10 Sep 2021
MRD: from clinical trials to clinical practice 1:43
MRD: from clinical trials to clinical practice
Katja Weisel • 10 Sep 2021

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals